Pioglitazone
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Diabetes Medications | Pioglitazone | 15-45mg PO Q24H | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 356 | <1 | 3-7 | N/A | >99 | 0.63 | N/A | No (N/A) |
References:
- Abe M, Kikuchi F, Okada K, Matsumoto K. Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis. Therapeutic apheresis and dialysis. 2009;13(3):238-9.
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01132